

Market Announcement

1 September 2025

Argenica Therapeutics Limited (ASX: AGN) – Trading Halt

Trading in the securities of Argenica Therapeutics Limited ('AGN') will be halted at the request of AGN, pending the release of an announcement by AGN.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Wednesday, 3 September 2025; or
- the release of the announcement to the market.

AGN's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

Australian Stock Exchange Limited
Level 40, Central Park
152-158 St George's Terrace
Perth WA 6000

1 September 2025

By email: tradinghaltsperth@asx.com.au

TRADING HALT REQUEST

Pursuant to ASX Listing Rule 17.1, Argenica Therapeutics Limited (“Argenica” or “the Company”) (ASX Code: AGN) requests that an immediate trading halt be put on its securities pending an announcement by the Company regarding top line results of its Phase 2 ARG-007 acute ischaemic stroke clinical trial (“Clinical Trial”).

The Company requests that the trading halt remain in place until the earlier of commencement of normal trading on Wednesday 3 September 2025 or when the announcement concerning the Clinical Trial results is released.

The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Kind Regards,

Emma Waldon
Company Secretary

[ENDS]